Wave Life Sciences Reports Q3 2026 Results, Advances Clinical Programs

What happened

Wave Life Sciences reported third-quarter 2026 revenue of $13.2 million and a net loss of $61.9 million, compared with revenue of $7.6 million and a net loss of $53.9 million a year earlier. Cash and investments totaled $431.0 million at September 30, 2026.

Confirmed

Global impact / market context

Revenue rose but the net loss widened as research and administrative costs grew, so the company is spending more to advance its obesity, AATD and liver disease programs. Management expects current cash to fund operations into the third quarter of 2028, which reduces near-term fundraising pressure.

Analyst inference

Investors in drug developers typically weigh cash runway against spending growth. Here, higher costs and a larger loss are offset by more revenue and $431.0 million in cash, plus a $12 million GSK milestone expected in the fourth quarter that is not included in the runway estimate.

Analyst inference

What to watch

1. The company expects a $12 million GSK milestone payment in the fourth quarter of 2026, and this amount is not included in its estimate that current resources fund operations into the third quarter of 2028. Confirmed
2. Watch whether dosing progress in the Phase 2a monotherapy study of WVE-007, the obesity program, supports the next development step, since the article says dosing is underway. Proposed
3. Track research and development expenses, which rose to $53.8 million from $45.9 million, because continued increases would shorten the cash runway that management projects. Analyst inference

Evidence

• Original source link unavailable